Golden Lab LLC was cited for marketing unapproved new drugs and misbranded products, specifically three ocular health supplement capsules sold under the DoctoRx's Optimal Formula and Alereve brand names. The company made disease claims on product labels and its website indicating the products were intended to treat, mitigate, or prevent conditions including glaucoma, ocular hypertension, and seasonal allergies—claims that classified them as drugs requiring FDA approval. Examples of violations included statements such as "Take if suffering from glaucoma or ocular hypertension" and "Reduces IOP & Increases Blood Flow" on labels, and marketing language describing the formula as "designed specifically for patients suffering from glaucoma, ocular hypertension, or those with a strong family history of glaucoma" on the company website. The inspection was conducted in November 2021 at the company's Jacksonville, Florida facility.